$4.98
+0.52 (+11.66%)
Open$4.41
Previous Close$4.46
Day High$5.04
Day Low$4.40
52W High$6.93
52W Low$1.08
Volume—
Avg Volume97.4K
Market Cap28.95M
P/E Ratio—
EPS$-3.95
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+767.5% upside
Current
$4.98
$4.98
Target
$43.20
$43.20
$28.55
$43.20 avg
$44.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 147.0K | 1.69M | 1.69M |
| Net Income | -25,954,629 | 118.4K | 113.8K |
| Profit Margin | -17,634.9% | 7.0% | 6.8% |
| EBITDA | -28,759,417 | 180.1K | 185.2K |
| Free Cash Flow | — | 113.7K | 84.7K |
| Rev Growth | — | -7.6% | +15.2% |
| Debt/Equity | 0.09 | 0.66 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |